Tags

Type your tag names separated by a space and hit enter

Blockade of D1 dopamine receptors in the medial prefrontal cortex attenuates amphetamine- and methamphetamine-induced locomotor activity in the rat.
Brain Res. 2009 Dec 01; 1300:51-7.BR

Abstract

The medial prefrontal cortex (mPFC) is a component of the mesolimbic dopamine (DA) system involved in psychostimulant-induced hyperactivity and previous studies have shown that altering DA transmission or D2 receptors within the mPFC can decrease this stimulant effect. The goal of this study was to investigate a potential modulatory role for D1 receptors in the mPFC in amphetamine (AMPH)- and methamphetamine (METH)-induced hyperactivity. Locomotor activity in an open-field arena was measured in male, Sprague-Dawley rats given an intra-mPFC infusion of vehicle or the D1 receptor antagonist SCH 23390 (0.25 or 1.0 microg) prior to systemic (i.p.) injection of saline, AMPH (1 mg/kg), or METH (1 mg/kg). We found that SCH 23390 produced a dose-dependent decrease in AMPH- and METH-induced locomotion and rearing but had no significant effect on spontaneous behavior that occurred following systemic saline injections. Because SCH 23390 has been shown to have agonist-like properties at 5-HT(2C) receptors, a follow-up experiment was performed to determine if this contributed to the attenuation of METH-induced activity that we observed. Rats were given intra-mPFC infusions of both SCH 23390 (1.0 microg) and the 5-HT(2C) antagonist RS 102221 (0.25 microg) prior to METH (1 mg/kg, i.p.). The addition of the 5-HT(2C) antagonist failed to alter SCH 23390-induced decreases in METH-induced locomotion and rearing; infusion of RS 102221 alone had no significant effects on locomotion and produced a non-significant decrease in rearing. The results of these studies suggest that D1 activation in the mPFC plays a significant role in AMPH- and METH-induced hyperactivity.

Authors+Show Affiliations

Department of Psychology and Neuroscience Program, University of Illinois at Urbana-Champaign, 731 Psychology Bldg MC-716, 603 E Daniel St, Champaign, IL 61820, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19733155

Citation

Hall, Darien A., et al. "Blockade of D1 Dopamine Receptors in the Medial Prefrontal Cortex Attenuates Amphetamine- and Methamphetamine-induced Locomotor Activity in the Rat." Brain Research, vol. 1300, 2009, pp. 51-7.
Hall DA, Powers JP, Gulley JM. Blockade of D1 dopamine receptors in the medial prefrontal cortex attenuates amphetamine- and methamphetamine-induced locomotor activity in the rat. Brain Res. 2009;1300:51-7.
Hall, D. A., Powers, J. P., & Gulley, J. M. (2009). Blockade of D1 dopamine receptors in the medial prefrontal cortex attenuates amphetamine- and methamphetamine-induced locomotor activity in the rat. Brain Research, 1300, 51-7. https://doi.org/10.1016/j.brainres.2009.08.084
Hall DA, Powers JP, Gulley JM. Blockade of D1 Dopamine Receptors in the Medial Prefrontal Cortex Attenuates Amphetamine- and Methamphetamine-induced Locomotor Activity in the Rat. Brain Res. 2009 Dec 1;1300:51-7. PubMed PMID: 19733155.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Blockade of D1 dopamine receptors in the medial prefrontal cortex attenuates amphetamine- and methamphetamine-induced locomotor activity in the rat. AU - Hall,Darien A, AU - Powers,John P, AU - Gulley,Joshua M, Y1 - 2009/09/03/ PY - 2009/07/09/received PY - 2009/08/19/revised PY - 2009/08/22/accepted PY - 2009/9/8/entrez PY - 2009/9/8/pubmed PY - 2010/1/6/medline SP - 51 EP - 7 JF - Brain research JO - Brain Res. VL - 1300 N2 - The medial prefrontal cortex (mPFC) is a component of the mesolimbic dopamine (DA) system involved in psychostimulant-induced hyperactivity and previous studies have shown that altering DA transmission or D2 receptors within the mPFC can decrease this stimulant effect. The goal of this study was to investigate a potential modulatory role for D1 receptors in the mPFC in amphetamine (AMPH)- and methamphetamine (METH)-induced hyperactivity. Locomotor activity in an open-field arena was measured in male, Sprague-Dawley rats given an intra-mPFC infusion of vehicle or the D1 receptor antagonist SCH 23390 (0.25 or 1.0 microg) prior to systemic (i.p.) injection of saline, AMPH (1 mg/kg), or METH (1 mg/kg). We found that SCH 23390 produced a dose-dependent decrease in AMPH- and METH-induced locomotion and rearing but had no significant effect on spontaneous behavior that occurred following systemic saline injections. Because SCH 23390 has been shown to have agonist-like properties at 5-HT(2C) receptors, a follow-up experiment was performed to determine if this contributed to the attenuation of METH-induced activity that we observed. Rats were given intra-mPFC infusions of both SCH 23390 (1.0 microg) and the 5-HT(2C) antagonist RS 102221 (0.25 microg) prior to METH (1 mg/kg, i.p.). The addition of the 5-HT(2C) antagonist failed to alter SCH 23390-induced decreases in METH-induced locomotion and rearing; infusion of RS 102221 alone had no significant effects on locomotion and produced a non-significant decrease in rearing. The results of these studies suggest that D1 activation in the mPFC plays a significant role in AMPH- and METH-induced hyperactivity. SN - 1872-6240 UR - https://www.unboundmedicine.com/medline/citation/19733155/Blockade_of_D1_dopamine_receptors_in_the_medial_prefrontal_cortex_attenuates_amphetamine__and_methamphetamine_induced_locomotor_activity_in_the_rat_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0006-8993(09)01816-2 DB - PRIME DP - Unbound Medicine ER -